Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16466248 | 0.89 | FFAR4 (0.50) | FFAR4GPR119KDM4EPKMUSP2 | |
| SCHEMBL17125240 | 0.88 | GPR119 (0.43) | FFAR4GPR119KDM4EPKMUSP2 | |
| SCHEMBL16465364 | 0.88 | NR1H2 (0.47) | GPR119KDM4EPKMUSP2SMN1; SMN2 | |
| SCHEMBL16464954 | 0.83 | MEN1 (0.42) | GPR119KDM4EPKMUSP2SMN1; SMN2 | |
| SCHEMBL30864016 | 0.82 | USP2 (0.44) | GPR119KDM4EUSP2SMN1; SMN2RECQL | |
| SCHEMBL10146435 | 0.82 | USP2 (0.43) | FFAR4GPR119KDM4EPKMUSP2 | |
| SCHEMBL16466447 | 0.81 | GPR119 (0.46) | GPR119 | |
| SCHEMBL368761 | 0.81 | USP2 (0.45) | GPR119KDM4EUSP2SMN1; SMN2RECQL | |
| SCHEMBL1224898 | 0.81 | GPR119 (0.54) | FFAR4GPR119 | |
| SCHEMBL21636211 | 0.80 | USP2 (0.44) | GPR119KDM4EUSP2SMN1; SMN2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906542-B1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2906542-B1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9708270-B2 | Substituted spiropiperidinyl compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708270-B2 | Substituted spiropiperidinyl compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708270-B2 | Substituted spiropiperidinyl compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150274672-A1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274672-A1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274672-A1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2906542-A2 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014059232-A2 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014059232-A2 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274672-A1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR180, GPR88 | FFAR4 27/4885GPR119 1/4885KDM4E 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.